Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard F. Ambinder

Showing results (161-170 of 218) with videos related to

Pageof 22
Sort By:
Leukemia & Lymphoma|July 28, 2012
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemiaYvette L Kasamon, Robert A Brodsky, Michael J Borowitz, et al.
Leukemia & Lymphoma|August 22, 2015
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamideLindsey R Lombardi, Christopher G Kanakry, Marianna Zahurak, et al.
The Lancet. Haematology|August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialCatherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2017
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Clinical Chemistry|May 26, 2025
Full-Length Clonal Immunoglobulin Rearrangements in cfDNA: Improved Recovery and SequencingRena R Xian, Prisca Mbonu, Lisa M Haley, et al.
Blood|May 21, 2020
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)Juan C Ramos, Joseph A Sparano, Amy Chadburn, et al.
Blood Advances|September 8, 2019
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70Philip H Imus, Hua-Ling Tsai, Leo Luznik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2007
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphomaJavier Bolaños-Meade, Elizabeth Garrett-Mayer, Leo Luznik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2018
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow TransplantationYvette L Kasamon, Ephraim J Fuchs, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2015
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA FactorsJennifer A Kanakry, Christopher D Gocke, Javier Bolaños-Meade, et al.
Pageof 22

Showing results (161-170 of 218) with videos related to

Sort By:
Pageof 22
Leukemia & Lymphoma|July 28, 2012
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemiaYvette L Kasamon, Robert A Brodsky, Michael J Borowitz, et al.
Leukemia & Lymphoma|August 22, 2015
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamideLindsey R Lombardi, Christopher G Kanakry, Marianna Zahurak, et al.
The Lancet. Haematology|August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialCatherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2017
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Clinical Chemistry|May 26, 2025
Full-Length Clonal Immunoglobulin Rearrangements in cfDNA: Improved Recovery and SequencingRena R Xian, Prisca Mbonu, Lisa M Haley, et al.
Blood|May 21, 2020
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)Juan C Ramos, Joseph A Sparano, Amy Chadburn, et al.
Blood Advances|September 8, 2019
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70Philip H Imus, Hua-Ling Tsai, Leo Luznik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2007
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphomaJavier Bolaños-Meade, Elizabeth Garrett-Mayer, Leo Luznik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2018
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow TransplantationYvette L Kasamon, Ephraim J Fuchs, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2015
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA FactorsJennifer A Kanakry, Christopher D Gocke, Javier Bolaños-Meade, et al.
Pageof 22